Daniel Zelterman
Affiliations: | Yale University, New Haven, CT |
Area:
Biostatistics BiologyGoogle:
"Daniel Zelterman"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Crump K, Crouch E, Zelterman D, et al. (2020) Accounting for Multiple Comparisons in Statistical Analysis of the Extensive Bioassay Data on Glyphosate. Toxicological Sciences. 175: 156-167 |
| Abu-Khalaf M, Pierobon M, Denduluri N, et al. (2019) Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3) Cancer Research. 79 |
| Han G, Schell MJ, Zhang H, et al. (2016) Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. Biometrics |
| Stahl M, Podoltsev NA, DeVeaux M, et al. (2016) The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort Blood. 128: 1063-1063 |
| Acevedo-Gadea C, Hatzis C, Chung G, et al. (2015) Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. Breast Cancer Research and Treatment. 150: 157-67 |
| Ratner ES, Keane FK, Lindner R, et al. (2012) A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31: 4559-66 |
| Saif MW, Hashmi S, Zelterman D, et al. (2008) Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review International Journal of Colorectal Disease. 23: 139-145 |